Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 100 /hr

★★★★★

☆☆☆☆☆

Hire Nick B.

United States

USD 100 /hr

Protein science PhD, CEO of skin tissue engineering startup, ex-venture capital / business development and strategy

Profile Summary

CEO of an autologous skin cell therapeutics company for rare disease and wound healing. Extensive experience in protein therapeutics development, conjugation, purification, cell culture, tissue engineering, protein dynamics simulations and experiments (hydrogen-deuterium exchange)

Subject Matter Expertise

• ☆ Computational Biology
• ☆ Biochemistry
• ☆ Biochemical Assays
• ☆ Structural Biology
• ☆ Binding Assays
• ☆ Molecular Biology
• ☆ Biomarkers
• ☆ Plasmid DNA
• ☆ Monoclonal Antibody Production
• ☆ Cell Biology
• ☆ Cell-Based Assays
• ☆ Biophysics
• ☆ Biotechnology & Bioengineering
• ☆ Recombinant Protein Expression
• ☆ Biomedical Engineering
• ☆ Biomechanics
• ☆ Biological Engineering
• ☆ Cell Culture
• ☆ Primary Cells
• ☆ 3D Cell Culture
• ☆ Synthetic Biology
• ☆ Chemical Biology
• ☆ Biomolecular Engineering
• ☆ Genetic Engineering
• ☆ Protein/Enzyme Engineering
• ☆ Gene Delivery
• ☆ Tissue Engineering
• ☆ Product Evaluation
• ☆ Concept Development
• ☆ Hypothesis
• ☆ Peer Review
• ☆ Research Methodology
• ☆ Literature Search
• ☆ Gap Analysis
• ☆ Presentation Design
• ☆ Technical & Scientific Writing
• ☆ Manuscript & Journal Article Writing
• ☆ Science Communication
• ☆ Scientific Proofreading & Editing
• ☆ Proofreading & Editing
• ☆ Grant Writing
• ☆ Business Strategy
• ☆ Entrepreneurship
• ☆ Business Intelligence
• ☆ Innovation Management
• ☆ Project Management

Services

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Technical Writing, General Proofreading & Editing

Research Market Research, User Research, Technology Scouting, Fact Checking, Gap Analysis, Scientific and Technical Research, Systematic Literature Review

Consulting Business Strategy Consulting, Scientific and Technical Consulting

Data & AI Data Processing, Data Insights

Product Development Formulation, Product Validation, Concept Development

Work Experience

CEO/Founder

AddGraft Therapeutics

November 2025 - Present

Research Strategy Consultant

Arcadia Science

November 2025 - December 2025

Innovation Fellow

Scion Life Sciences

December 2024 - September 2025

Graduate Student Researcher

University of Chicago

August 2019 - July 2025

Senior Analyst

Kendall Capital Partners

August 2024 - November 2024

BIo Fellow

Insight Partners

January 2024 - June 2024

Senior Research Associate

Rubius Therapeutics Inc

June 2017 - August 2019

Research Associate

Immunogen Inc

June 2015 - May 2017

Coop Researcher

Genentech Inc

June 2014 - May 2015

Education

Graduate Student (Biophysical Sciences Graduate Program)

University of Chicago

August 2019 - Present

PhD, Biophysical Sciences

University of Chicago

August 2019 - July 2025

Masters of Science (Biomedical Engineering)

Tufts University

May 2013 - May 2014

Bachelors of Science (Biomedical Engineering)

Tufts University

September 2009 - May 2013

Certifications

• Certification details not provided.

Publications

PREPRINT

Jordan M Mancl, Wenguang G Liang, Nicholas L Bayhi, Hui Wei, William Budell, Joshua H Mendez, Tobin R Sosnick, Bridget Carragher, Clinton S Potter, Wei-Jen Tang (2025). Characterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity .

Jordan M Mancl, Wenguang G Liang, Nicholas L Bayhi, Hui Wei, William Budell, Joshua H Mendez, Tobin R Sosnick, Bridget Carragher, Clinton S Potter, Wei-Jen Tang (2025). Characterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity .

Jordan M. Mancl, Wenguang G. Liang, Nicholas L. Bayhi, Hui Wei, William Budell, Joshua H. Mendez, Tobin R. Sosnick, Bridget Carragher, Clinton S. Potter, Wei-Jen Tang (2024). Characterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity .

JOURNAL ARTICLE

(2021). Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15 . Cancer immunology, immunotherapy : CII.

(2021). Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic . Nature communications.